Rhythm Pharmaceuticals Announces Q3 Revenue Growth and Phase III Trial Timeline for Bivamelagon
Rhythm Pharmaceuticals (RYTM) reported strong third-quarter financial results, highlighted by $92 million in revenue driven by the successful initial launch of its product in the United States. CEO David Meeker noted that the company's commercial performance has exceeded expectations during this early rollout phase. Looking ahead, the company committed to a $350 million royalty buy-down strategy and announced that it expects to begin dosing the first Phase III patients with bivamelagon for hypoparathyroidism (HO) in January. These developments signal an aggressive push toward expanding its clinical pipeline and optimizing its long-term revenue structure.
Tickers: $RYTM
Topics: earnings product launch revenue
Read the full article at Seeking Alpha
Part of the story Rhythm Pharmaceuticals Announces Q3 Revenue Growth and Phase III Trial Timeline for Bivamelagon (2 articles)